A5068157704- Adolescent and Pediatric Healthcare
- Autoimmune and Inflammatory Disorders Research
- Rheumatoid Arthritis Research and Therapies
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Immunodeficiency and Autoimmune Disorders
- Whipple's Disease and Interleukins
- Child and Adolescent Health
- Inflammasome and immune disorders
- Intramuscular injections and effects
- Pediatric health and respiratory diseases
- Childhood Cancer Survivors' Quality of Life
- Human Health and Disease
- Systemic Lupus Erythematosus Research
Juvenile idiopathic arthritis (JIA) is the most frequent rheumatic disease of childhood. The goal juvenile therapy to achieve durable clinical and laboratory remission a good quality life. Various groups drugs are used in treatment JIA, one which anti-CD20 drug rituximab. Rituximab causes B-cell depletion, may lead decreased immunoglobulin levels, antigen-presenting function B-lymphocytes impaired T-cell response. main side effects rituximab administration infusion reactions,...
The efficacy of JAK-kinase inhibitors in autoimmune diseases is due to the peculiarities their pathogenesis, involvement various cytokines that trigger cascade inflammatory reactions, enhance transcriptional response disease-induced or disease-associated genes and potentiate production proinflammatory cytokines. Only tofacitinib currently approved for use pediatric rheumatic diseases. Given literature data on other adult diseases, we assume possibility patients. Objective. To evaluate safety...
Systemic juvenile idiopathic arthritis (sJIA) is of one or more joints accompanied preceded by confirmed intermittent fever at least 3 days duration for 2 weeks in combination with the following features: transient (volatile) erythematous rash, generalized lymphadenopathy, hepatomegaly and/or splenomegaly, serositis. Prior to invention genetically engineered biological drugs (GEBDs), therapeutic options patients JIA were limited use nonsteroidal anti-inflammatory (NSAIDs),...
Periodic syndrome associated with variants in the Tumor Necrosis Factor receptor gene (hereinafter referred to as TNFRSF1A gene) – Associated periodic TRAPS) is an autoinflammatory genetic disease that often occurs under "mask" of juvenile arthritis (JA), well other rheumatic diseases. Knowledge phenotypic and features will allow timely verification diagnosis initiation pathogenetic therapy, thereby reducing risk patient disability, complications improving prognosis. Objective. To identify...
New coronavirus infection (COVID-19) is an acute respiratory disease caused by the SARS-CoV-2 coronavirus. Tixagevimab+cilgavimab has been developed for prevention and treatment of COVID-19. The purpose this research was to evaluate safety use two-component drug monoclonal antibodies (tixagevimab+cilgavimab) pre-exposure prophylaxis new in children with rheumatic diseases (RDs). Materials methods used: a single-center retrospective study prospective stage had carried out that included 300...
Severe acute respiratory syndrome virus SARS-CoV-2 is associated with the phenomenon of immune system dysregulation, which may serve as a trigger for development autoimmune diseases and secondary hemophagocytic (vHPS). Objective. To determine peculiarities clinical laboratory manifestations sHPS in children rheumatic (RD) developed after NCI (COVID-19). Patients methods. The study included 116 pediatric patients RH who underwent examination treatment at rheumatology department National...
Rationale. Children with rheumatic diseases receiving immunosuppressants and/or genetically engineered biopharmaceutical drugs (GEBDs) glucocorticosteroids (GCs) are at high risk of developing severe long-term symptoms novel coronavirus infection. The possibilities pre-exposure prophylaxis COVID-19 in this patient population significantly limited due to the risks insufficient immunogenicity vaccine presence secondary immunodeficiency developed under conditions immunosuppressive therapy and...
Background. A register is a critical component of the healthcare system. It consists informational part (number patients, spectrum and severity pathology, dynamics each patient's condition, administration specific drugs, therapeutic effects) an analytical (treatment efficacy, planning individual regional needs for drugs effects, development evaluation management protocols, etc.). In Russia, despite existence National Federal Register, number parameters collected limited; Register lacks...
Juvenile idiopathic arthritis (JIA) is of unknown cause lasting more than 6 weeks, which starts in children under 16 years old with the exclusion other joint disorder. According to recommendations for treatment JIA, patients who does not responded antirheumatic therapy, we prescribe biological primarily TNF-alpha inhibitors. Despite their high effectiveness, some patients, inhibitors has no proper therapeutic effect, requires studying possibility using particular- rituximab. Objective. To...
Juvenile arthritis (Syn.: Systemic adolescent idiopathic arthritis; hereinafter referred to as the JA, sJA) is most complex pathogenesis, severe process, and poorly predicted variant of arthritis. The characteristic sJA process development life-threatening complications, which may lead further functional multi organ failure, delayed physical development, patient disability. In this regard, it necessary diagnose disease correctly in early stages. Therefore, children suspected having should be...
Systemic juvenile idiopathic arthritis (syn.: with systemic onset; hereinafter referred to as sJIA) is one of the most severe variants arthritis, in which at beginning disease it often not joint damage that comes fore, but manifestations such fever, rash, hepatosplenomegaly, lymphadenopathy and serositis. Tumor necrosis factor-α (TNF-α) inhibitors, successfully used therapy JIA without manifestations, are effective patients JIA. Thus, according BIKER registry (Germany), remission was...